In Segment A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental participants will probably be enrolled in the determined monotherapy dosign program. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 might be offered as "incorporate-on" therapy. In Section C, https://abbv-744-safety-and-side02356.kylieblog.com/32472608/little-known-facts-about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers